Literature DB >> 9788402

Development of a head and neck companion module for the quality of life-radiation therapy instrument (QOL-RTI)

A Trotti1, D J Johnson, C Gwede, L Casey, B Sauder, A Cantor, J Pearlman.   

Abstract

PURPOSE/
OBJECTIVE: A review of available head and neck quality of life (QOL) instruments reveals them to inadequately address important radiation related side effects, or to be too cumbersome for routine use. The purpose of this study was to develop a head and neck disease specific module as a companion to the previously developed quality of life - radiation therapy instrument (QOL-RTI). The goal was to create a more complete, yet concise, head and neck site-specific module geared toward patients receiving radiation therapy for head and neck cancer. METHODS AND MATERIALS: This exploratory study included 34 consecutive patients undergoing definitive radiotherapy over a 6-7 week course (60-79.8 Gy). We developed and administered a 14-item questionnaire to all eligible patients treated with radiotherapy for head and neck cancer who were not already registered in another research study assessing quality of life (e.g., RTOG). During the treatment period, the QOL-RTI general tool and the head and neck (H&N) module were administered as follows: at baseline, at week four (for test-retest), and at the end of the treatment period. For validation purposes the QOL-RTI/H&N was compared to the functional assessment cancer tool head and neck (FACT-H&N) questionnaire. The FACT-H&N was administered one time at week 4, on the same day as the QOL-RTI/H&N. This report includes the treatment phase of the study (during the course of radiation).
RESULTS: Mean age was 62 years (range 40-75). Internal consistency of the module was satisfactory (Chronbach's alpha = 0.85). Test-retest yielded a correlation coefficient of 0.90 (p < 0.001). Concurrent validity, established by comparing the module to the FACT/H&amp;N , yielded a correlation coefficient of 0.85. Significant changes in quality of life scores during a course of radiation was noted for both general quality of life tool and the site specific module. For the head and neck module, the difference in the mean baseline (7.17) and end of treatment scores (4.20) was 2.94, or 42% change (p < 0.0001). A smaller, yet still significant, difference in scores was seen in the general QOL tool (22 % change, p = 0.001). Item analysis of the module revealed statistically significant (p < 0.05) worsening in quality of life scores in the following areas: pain in throat, swallowing difficulty (meat/bread and liquids), changes in mucous and saliva, changes in taste, difficulty chewing, trouble with coughing, and speech difficulties. Items that were not significant were pain in the mouth, and appearance.
CONCLUSION: These initial results suggest that the H&amp;N companion module to the QOL-RTI is a valid and reliable tool that is responsive to changes in QOL during a course of H&amp;N radiation therapy. This tool differs from existing H&amp;N tools by including specific assessments of mucous, saliva, taste, cough, and local pain in a concise format. Significant changes in QOL scores were noted in all of these items. Evaluation of the tool in the post-treatment period (follow-up) is ongoing.

Entities:  

Mesh:

Year:  1998        PMID: 9788402     DOI: 10.1016/s0360-3016(98)00224-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  12 in total

1.  Octreotide acetate in prevention of chemoradiation-induced diarrhea in anorectal cancer: randomized RTOG trial 0315.

Authors:  Babu Zachariah; Clement K Gwede; Jennifer James; Jaffer Ajani; Lisa J Chin; David Donath; Seth A Rosenthal; Brent L Kane; Marvin Rotman; Lawrence Berk; Lisa A Kachnic
Journal:  J Natl Cancer Inst       Date:  2010-03-25       Impact factor: 13.506

2.  Changing the perspective: current trends in the assessment of functional outcome in patients with head and neck cancer.

Authors:  Uta Tschiesner
Journal:  Curr Oncol Rep       Date:  2011-04       Impact factor: 5.075

3.  Brainstem dose is associated with patient-reported acute fatigue in head and neck cancer radiation therapy.

Authors:  Matthew J Ferris; Jim Zhong; Jeffrey M Switchenko; Kristin A Higgins; Richard J Cassidy; Mark W McDonald; Bree R Eaton; Kirtesh R Patel; Conor E Steuer; H Michael Baddour; Andrew H Miller; Deborah W Bruner; Canhua Xiao; Jonathan J Beitler
Journal:  Radiother Oncol       Date:  2017-08-18       Impact factor: 6.280

4.  Patient reported dry mouth: Instrument comparison and model performance for correlation with quality of life in head and neck cancer survivors.

Authors:  Mona Kamal; David I Rosenthal; Stefania Volpe; Ryan P Goepfert; Adam S Garden; Katherine A Hutcheson; Karine A Al Feghali; Mohamed Ahmed Mohamed Meheissen; Salman A Eraj; Amy E Dursteler; Bowman Williams; Joshua B Smith; Jeremy M Aymard; Joel Berends; Aubrey L White; Steven J Frank; William H Morrison; Richard Cardoso; Mark S Chambers; Erich M Sturgis; Tito R Mendoza; Charles Lu; Abdallah S R Mohamed; Clifton D Fuller; G Brandon Gunn
Journal:  Radiother Oncol       Date:  2017-12-08       Impact factor: 6.280

5.  Phase II trial of hyperfractionated intensity-modulated radiation therapy and concurrent weekly cisplatin for Stage III and IVa head-and-neck cancer.

Authors:  Patrick D Maguire; Michael Papagikos; Sue Hamann; Charles Neal; Martin Meyerson; Neil Hayes; Peter Ungaro; Kenneth Kotz; Marion Couch; Hoke Pollock; Joel Tepper
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04-08       Impact factor: 7.038

Review 6.  A systematic review of head and neck cancer quality of life assessment instruments.

Authors:  Bukola Ojo; Eric M Genden; Marita S Teng; Kathrin Milbury; Krzysztof J Misiukiewicz; Hoda Badr
Journal:  Oral Oncol       Date:  2012-04-21       Impact factor: 5.337

Review 7.  Quality-of-life outcomes in head and neck cancer patients.

Authors:  Randall P Morton; Mark E Izzard
Journal:  World J Surg       Date:  2003-07       Impact factor: 3.352

8.  Medical marijuana use in head and neck squamous cell carcinoma patients treated with radiotherapy.

Authors:  David A Elliott; Nima Nabavizadeh; Jeanna L Romer; Yiyi Chen; John M Holland
Journal:  Support Care Cancer       Date:  2016-03-23       Impact factor: 3.603

Review 9.  Content comparison of quality of life questionnaires used in head and neck cancer based on the international classification of functioning, disability and health: a systematic review.

Authors:  U Tschiesner; S N Rogers; U Harréus; A Berghaus; A Cieza
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-06       Impact factor: 2.503

10.  Quality of life and salivary output in patients with head-and-neck cancer five years after radiotherapy.

Authors:  Pètra M Braam; Judith M Roesink; Cornelis P J Raaijmakers; Wim B Busschers; Chris H J Terhaard
Journal:  Radiat Oncol       Date:  2007-01-05       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.